<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412918</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00014763</org_study_id>
    <nct_id>NCT01412918</nct_id>
  </id_info>
  <brief_title>Inhibitor Masking Device &amp; Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression</brief_title>
  <official_title>Clinical Evaluation of the Inhibitor Tinnitus Treatment Masking Device &amp; SCN9 Gene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device. To determine if
      there is a higher incident of expression of the sodium channel, voltage gated, type IX alpha
      subunit (SCN9) gene in those subjects with disturbing tinnitus than subjects that are not
      disturbed by tinnitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 50 million Americans have tinnitus on a regular basis with between 2-3 million
      suffering from tinnitus where it affects daily living. The Inhibitor™ Tinnitus Masking Device
      is a new tinnitus treatment device recently available in the United States for use of
      temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds
      via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided
      the opportunity to demonstrate the device to observe any changes in their tinnitus. The
      device may be demonstrated up to 5 times. The investigators will be recording the the degree
      and duration of change in tinnitus perception following treatment with the Inhibitor™
      Tinnitus Masking Device. Patients may provide a genetic sample (typically via saliva sample)
      to look for expression of a particular genetic marker that may be associated with tinnitus.
      The investigators will be collect samples from both people with tinnitus and those without
      tinnitus to use as a control.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of support to continue
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Percentage of Participants for Which the Inhibitor™ Tinnitus Masking Device Effected Tinnitus Perception</measure>
    <time_frame>Single visit (day 1), assessed the day of visit</time_frame>
    <description>Determine percentage of particpants with a change in tinnitus perception to evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Which Showed Presence of SCN9 Gene Expression.</measure>
    <time_frame>Single visit (day 1), evaluated at the time of the genetic collection.</time_frame>
    <description>Percentage of participants with and without tinnitus provided a genetic sample via saliva to determine presence of SCN9 gene expression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Tinnitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual with tinnitus. Intervention: inhibitor device demonstration.
The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No tinnitus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals without tinnitus will also be masked with the device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Inhibitor™ Tinnitus Masking Device</intervention_name>
    <description>The Inhibitor™ Tinnitus Masking Device</description>
    <arm_group_label>Tinnitus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 years,

          -  has tinnitus

        Exclusion Criteria:

          -  Pacemaker,

          -  pregnancy,

          -  metal implants in head or neck,

          -  thrombosis, migraines/headaches,

          -  metal bonded retainer, surgeries within the last 6 months which patient is still
             recovering from,

          -  any medical reason your physician would advise against the use of this device,

          -  under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Friedland, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert &amp; The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP, Drenth JP, Dai F, Wheeler J, Sanders F, Wood L, Wu TX, Karppinen J, Nikolajsen L, Männikkö M, Max MB, Kiselycznyk C, Poddar M, Te Morsche RH, Smith S, Gibson D, Kelempisioti A, Maixner W, Gribble FM, Woods CG. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5148-53. doi: 10.1073/pnas.0913181107. Epub 2010 Mar 8.</citation>
    <PMID>20212137</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <results_first_submitted>June 23, 2014</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Marcia Dewey, AuD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Tinnitus</keyword>
  <keyword>Inhibitor Device</keyword>
  <keyword>SCN9 gene</keyword>
  <keyword>Ringing in the ears</keyword>
  <keyword>Milwaukee</keyword>
  <keyword>Medical College of Wisconsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tinnitus</title>
          <description>Individual with tinnitus.
The Inhibitor™ Tinnitus Masking Device: The Inhibitor™ Tinnitus Masking Device</description>
        </group>
        <group group_id="P2">
          <title>No Tinnitus</title>
          <description>Individuals without tinnitus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline participants with tinnitus demonstrating the Inhibitor™ Tinnitus Masking Device.</population>
      <group_list>
        <group group_id="B1">
          <title>Tinnitus</title>
          <description>Individual with tinnitus.
The Inhibitor™ Tinnitus Masking Device: The Inhibitor™ Tinnitus Masking Device</description>
        </group>
        <group group_id="B2">
          <title>No Tinnitus</title>
          <description>Individuals without tinnitus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Percentage of Participants for Which the Inhibitor™ Tinnitus Masking Device Effected Tinnitus Perception</title>
        <description>Determine percentage of particpants with a change in tinnitus perception to evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device.</description>
        <time_frame>Single visit (day 1), assessed the day of visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tinnitus</title>
            <description>Tinnitus. genetic sample collection (no intervention)</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Percentage of Participants for Which the Inhibitor™ Tinnitus Masking Device Effected Tinnitus Perception</title>
          <description>Determine percentage of particpants with a change in tinnitus perception to evaluate the effectiveness of the Inhibitor™ Tinnitus Masking Device.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Which Showed Presence of SCN9 Gene Expression.</title>
        <description>Percentage of participants with and without tinnitus provided a genetic sample via saliva to determine presence of SCN9 gene expression.</description>
        <time_frame>Single visit (day 1), evaluated at the time of the genetic collection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tinnitus</title>
            <description>Individual with tinnitus.
The Inhibitor™ Tinnitus Masking Device: The Inhibitor™ Tinnitus Masking Device</description>
          </group>
          <group group_id="O2">
            <title>No Tinnitus</title>
            <description>Individuals without tinnitus.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Which Showed Presence of SCN9 Gene Expression.</title>
          <description>Percentage of participants with and without tinnitus provided a genetic sample via saliva to determine presence of SCN9 gene expression.</description>
          <units>% of participants with gene expression</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tinnitus</title>
          <description>Individual with tinnitus. Intervention: inhibitor device demonstration.
The Inhibitor™ Tinnitus Masking Device: The Inhibitor™ Tinnitus Masking Device</description>
        </group>
        <group group_id="E2">
          <title>No Tinnitus</title>
          <description>Individuals without tinnitus.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Friedland</name_or_title>
      <organization>Medical College of Wisconsion</organization>
      <phone>414-805-</phone>
      <email>dfriedland@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

